Are peptides legal in Delaware?

Can a Delaware resident get peptides by telehealth?

Delaware repealed its older physician telemedicine section (24 Del. C. 1769D) effective July 1, 2021 and moved telehealth rules for all professions into Title 24, chapter 60. Section 6001 defines telemedicine to include secure video conferencing and store and forward transfer, which may be synchronous or asynchronous. Section 6003 requires a health-care provider-patient relationship before telehealth care; the relationship may be established in person or through telehealth but must include verification of the patient's identity and location and disclosure of the provider's identity and credentials, and without a proper relationship a provider may not issue a prescription solely in response to an internet questionnaire, internet consult, or telephone consult. The Division of Professional Regulation also issues interstate telehealth registrations that let physicians and physician assistants licensed in good standing in another state treat Delaware patients by telehealth without a full Delaware license. Section 6003(b) answers the asynchronous question directly: telehealth services may be synchronous or asynchronous using store-and-forward technology, and telehealth may be used to establish the provider-patient relationship if the provider determines the provider can meet the same standard of care as an in-person visit. Section 6004(a) adds that before diagnosis and treatment the provider must do at least one of the following: an in-person exam, having another Delaware-licensed provider present with the patient, making the diagnosis using audio or visual communication, or meeting professional society guidelines for establishing a relationship in evidence-based telemedicine practice. An asynchronous first prescription is therefore allowed when those conditions are met, but not one issued solely from an internet questionnaire without a proper relationship. [2] [3] [4]

How does the Delaware pharmacy board treat compounding?

The Delaware Board of Pharmacy licenses pharmacies under Title 24, chapter 25 of the Delaware Code and its Board regulations. Delaware has no separate state bulks list, so peptide eligibility follows the federal 503A framework (approved drug component, USP or NF monograph, or FDA 503A bulks list). Chapter 25 was reorganized by 85 Del. Laws chapter 49, effective June 30, 2026; in the current Delaware Code, checked 2026-09-22, a pharmacy in another state that delivers, dispenses, or distributes a prescription drug to a Delaware patient must hold a Delaware nonresident pharmacy license (section 2535), which requires good standing in every state where it is licensed and the most recent Board-approved inspection report covering the business it will conduct in Delaware, performed by or for its home-state licensing authority (or, if the home state has not inspected, by a national pharmacy verification program or another qualified entity). It must designate a Delaware registered agent (section 2536), keep a valid home-state license, and may be disciplined for failing to send the Board later inspection reports within 60 days of receiving them (section 2537). The Board's regulations (24 Del. Admin. Code 2500) require all compounding to comply with section 503A of the federal act (regulation 5.1.6) and require every Board licensee that compounds to comply with USP chapters 795 and 797 (regulation 10.0). [1] [5] [6] [7] [9]

Can you get compounded GLP-1s in Delaware?

Delaware patients using an out-of-state telehealth GLP-1 program should confirm the prescriber is Delaware-licensed or holds an interstate telehealth registration, and that the pharmacy holds a Delaware nonresident pharmacy license. [4] [6] [12]

Prices by channel: semaglutide cost, tirzepatide cost.

Approvals, shortage history, and prices for every GLP-1 we track are on the GLP-1 hub.

What is the legal access path in Delaware?

Find a provider in Delaware

• Compounding pharmacies in Delaware
• Clinics in Delaware
• Telehealth providers in Delaware

Is it legal to buy research peptides in Delaware?

Only Delaware-licensed pharmacies and licensed nonresident pharmacies may dispense prescription drugs to Delaware patients. "Research use only" peptides sold for human injection are unapproved new drugs under federal law, are not dispensed by a pharmacist, and fall outside Delaware's pharmacy licensing system. Delaware's own food and drug law (16 Del. C. chapter 33, Pure Food and Drugs) prohibits manufacturing or selling an adulterated or misbranded drug (section 3302) but has no separate new-drug approval provision, so the prohibition on selling unapproved new drugs comes from federal law. [6] [8] [13]

Peptide-specific notes for Delaware

Frequently asked questions

Sources

Numbered citations above point to these primary sources: the state statute or rule, the pharmacy board, and federal FDA guidance.